The novel anticoagulants: Entering a new era

Swiss Medical Weekly

Volumn 139, Issue 5-6, 2009, Pages 60-64

  Bounameaux, Henri ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anticoagulant treatment; Dabigatran etexilate; Factor Xa; Rivaroxaban; Thrombin

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; AVIDIN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; ENOXAPARIN; FLUINDIONE; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; RIVAROXABAN; SSR 12517E; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XARELTO; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INHIBITION KINETICS; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER TOXICITY; LUNG EMBOLISM; ORTHOPEDIC SURGERY; POSTOPERATIVE CARE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TABLET; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 60149104694     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133: 454S-545S.
2. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet. 2002;359 (9319):1710-1.
3. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-5; discussion 2053-5.
4. Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357(11):1094-104.
5. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371(9609):315-21.
6. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949- 56.
7. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost. 2007;5(11): 2178-85.
8. Ginsberg JS, Davidson BL, Comp PC, et al. The oral thrombin Inhibitor dabigatran etexilate vs the North-American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2008.
9. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-75.
10. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86.
11. Turpie AG, Bauer KA, Davidson B, et al. Comparison of rivaroxaban, an oral direct Factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study). 2008: Proceedings of the 9th EFORT Congress, Nice, May 30, 2008. Abstract F85.
12. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372 (9632):31-9.
13. Weitz J, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:234S-256S.